What is Orbit Genomics?
Orbit Genomics is an early-stage genomics company dedicated to revolutionizing the diagnosis, treatment, and prevention of intricate diseases. Their focus spans critical areas such as cancer, cardiovascular conditions, and neurological disorders, leveraging cutting-edge genomic technologies to drive innovation in healthcare.
How much funding has Orbit Genomics raised?
Orbit Genomics has raised a total of $3.8M across 2 funding rounds:
Unspecified
$3M
Debt
$780K
Unspecified (2022): $3M with participation from New Horizon Health and NHH Ventures
Debt (2025): $780K, investors not publicly disclosed
Key Investors in Orbit Genomics
New Horizon Health
New Horizon Health is a venture capital firm specializing in the biotechnology and healthcare sectors, likely focusing on companies with innovative diagnostic or therapeutic platforms.
NHH Ventures
NHH Ventures appears to be an investment arm or affiliate, potentially focused on early-stage or strategic investments within the health and life sciences industry.
What's next for Orbit Genomics?
The recent major strategic investment, alongside the overall enterprise-level funding, positions Orbit Genomics for accelerated growth and expanded research and development initiatives. This capital infusion is expected to fuel the company's mission to translate genomic insights into actionable clinical applications, potentially leading to breakthroughs in personalized medicine and disease management. The company's trajectory suggests a strong emphasis on scaling its diagnostic platforms and therapeutic development pipelines.
See full Orbit Genomics company page
